Switzerland-based Alcon’s dry eye disease drug ... and COMET-3 (NCT05360966) trials enrolled more than 930 patients, aged 30 years and older, with dry eye disease. The studies met their primary ...

Alcon operates in two segments: vision care and surgical. Vision care made up 43% of fiscal 2023 total ... toric and multifocal lenses will benefit Alcon as these lenses have a 15%-30% pricing ...